EP3755312A4 - DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION - Google Patents

DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION Download PDF

Info

Publication number
EP3755312A4
EP3755312A4 EP19756920.5A EP19756920A EP3755312A4 EP 3755312 A4 EP3755312 A4 EP 3755312A4 EP 19756920 A EP19756920 A EP 19756920A EP 3755312 A4 EP3755312 A4 EP 3755312A4
Authority
EP
European Patent Office
Prior art keywords
methods
dosage forms
enantiomerically enriched
pure bupropion
bupropion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19756920.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3755312A1 (en
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of EP3755312A1 publication Critical patent/EP3755312A1/en
Publication of EP3755312A4 publication Critical patent/EP3755312A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19756920.5A 2018-02-23 2019-02-25 DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION Pending EP3755312A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (2)

Publication Number Publication Date
EP3755312A1 EP3755312A1 (en) 2020-12-30
EP3755312A4 true EP3755312A4 (en) 2022-03-16

Family

ID=67688503

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19756920.5A Pending EP3755312A4 (en) 2018-02-23 2019-02-25 DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION

Country Status (19)

Country Link
EP (1) EP3755312A4 (enrdf_load_stackoverflow)
JP (3) JP2021513998A (enrdf_load_stackoverflow)
KR (3) KR20230075531A (enrdf_load_stackoverflow)
CN (1) CN112087999A (enrdf_load_stackoverflow)
AU (3) AU2019223187B2 (enrdf_load_stackoverflow)
BR (1) BR112020017179A2 (enrdf_load_stackoverflow)
CA (1) CA3092076A1 (enrdf_load_stackoverflow)
CL (1) CL2020002166A1 (enrdf_load_stackoverflow)
CR (1) CR20200415A (enrdf_load_stackoverflow)
EC (1) ECSP20060179A (enrdf_load_stackoverflow)
IL (2) IL313368A (enrdf_load_stackoverflow)
MA (1) MA51914A (enrdf_load_stackoverflow)
MX (2) MX2020008704A (enrdf_load_stackoverflow)
MY (1) MY202993A (enrdf_load_stackoverflow)
NI (1) NI202000056A (enrdf_load_stackoverflow)
NZ (1) NZ767378A (enrdf_load_stackoverflow)
PE (1) PE20211752A1 (enrdf_load_stackoverflow)
SG (1) SG11202008056SA (enrdf_load_stackoverflow)
WO (1) WO2019165379A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313368A (en) * 2018-02-23 2024-08-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
WO2021055124A1 (en) * 2019-09-20 2021-03-25 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2318960A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
DE60330909D1 (de) * 2003-08-08 2010-02-25 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
IL313368A (en) * 2018-02-23 2024-08-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Also Published As

Publication number Publication date
CA3092076A1 (en) 2019-08-29
KR20240091043A (ko) 2024-06-21
IL276871A (en) 2020-10-29
EP3755312A1 (en) 2020-12-30
BR112020017179A2 (pt) 2020-12-22
CR20200415A (es) 2021-02-03
ECSP20060179A (es) 2020-12-31
NZ767378A (en) 2024-03-22
MX2023009281A (es) 2023-08-17
MY202993A (en) 2024-05-31
JP2024075655A (ja) 2024-06-04
AU2022204521A1 (en) 2022-07-21
CL2020002166A1 (es) 2020-10-23
MA51914A (fr) 2020-12-30
SG11202008056SA (en) 2020-09-29
IL276871B1 (en) 2024-07-01
KR20230075531A (ko) 2023-05-31
JP2021513998A (ja) 2021-06-03
AU2019223187A1 (en) 2020-09-17
WO2019165379A1 (en) 2019-08-29
AU2022204521B2 (en) 2024-09-05
AU2024205858A1 (en) 2024-09-05
IL313368A (en) 2024-08-01
JP2022153638A (ja) 2022-10-12
MX2020008704A (es) 2020-12-07
CN112087999A (zh) 2020-12-15
KR20210003091A (ko) 2021-01-11
AU2019223187B2 (en) 2022-07-28
NI202000056A (es) 2021-01-11
PE20211752A1 (es) 2021-09-06
IL276871B2 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
EP3868367A4 (en) Micro-effervescent buccal tablet and preparation method thereof
EP3755312A4 (en) DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION
EP3733715A4 (en) TRIACORPS, ITS PREPARATION PROCESS AND ITS USE
EP3665181A4 (en) COMPOSITIONS AND PROCEDURES FOR DECOLONIZATION OF ANTIBIOTIC-RESISTANT BACTERIA IN THE INTESTINAL
EP3749315A4 (en) ALPHA-POLYGLUTAMATED RALTITREXED AND USES THEREOF
IL287905A (en) A pharmaceutical preparation containing brexanolone, gnaxolone or zoranolone and its use
EP3507977A4 (en) SYSTEMS AND METHODS FOR ENCODING AND PLAYING 360-DEGREE VIEW VIDEO CONTENT
EP3275454A4 (en) Pharmaceutical composition containing silybin, ve and l-carnitine
EP3760616A4 (en) 4-METHYLDIHYDROPYRIMIDINONE COMPOUND AND ITS MEDICINAL USE
EP3749122A4 (en) EVAPORATOR
EP3813842A4 (en) PHARMACEUTICAL COMPOSITION AND MANUFACTURING PROCESS THEREOF
SG11202104371XA (en) 1,3,4-oxadiazolone compound and pharmaceutical
EP3889219A4 (en) POLYCARBONATE COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF
EP3773541A4 (en) ISOTOPICALLY MODIFIED COMPOSITION AND ITS THERAPEUTIC USES
EP3244884A4 (en) Intravenous baclofen formulations and treatment methods
GB201908229D0 (en) Microneedles and methods for the manufacture thereof
EP3787639A4 (en) USE AND THERAPEUTIC METHODS
EP3677267A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF
HK40041795A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
HK40066587A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
HK40068404A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
EP4031121A4 (en) DOSAGE FORMS AND METHODS FOR FORMING ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
HK1257997A1 (zh) β受体阻滞剂的S-对映体富集组合物用於治疗肌肉无力
EP3402827A4 (en) OLIGOSACCHARIDE COMPOSITION, METHOD AND USE THEREOF
WO2015162070A3 (de) Orales abgabesystem

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TABUTEAU, HERRIOT

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40041795

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20220210BHEP

Ipc: A61P 25/30 20060101ALI20220210BHEP

Ipc: A61P 25/28 20060101ALI20220210BHEP

Ipc: A61P 25/24 20060101ALI20220210BHEP

Ipc: A61P 25/18 20060101ALI20220210BHEP

Ipc: A61P 25/00 20060101ALI20220210BHEP

Ipc: A61K 31/485 20060101ALI20220210BHEP

Ipc: A61K 31/137 20060101AFI20220210BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230306

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AXSOME THERAPEUTICS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241014